Objective To explore the clinical characteristics of syndrome of inappropriate antidiu- retic hormone secretion (SIADH) induced by duloxetine. Methods The diagnosis and treatment of a patient with duloxetine-related SIADH who was admitted to Nanjing Drum Tower Hospital Affiliated to Medical College of Nanjing University was reported, and the main clinical data (gender, age, prevalent diseases, use of duloxetine, combined medication, occurrence of SIADH, and intervention and outcome) of the case and related cases collected from the PubMed and Embase databases (up to December 31, 2021) were analyzed by descriptive statistics. Results A total of 27 patients were included in the analysis, including 6 males and 21 females, aged from 38 to 92 years with a median age of 74 years. duloxetine with daily dose of 20, 30, 40, 60-mg and unknown dose were in 5, 9, 1, 10 and 2 patients, respectively, and one patient with daily dose of 30-mg developed SIADH after a single overdose of 450-mg. Sixteen patients were treated with drugs that may cause hyponatremia or interact with duloxetine. Among them, 6, 2, 6, and 2 patients were treated with 1, 2, 3, and 4 drugs, respectively. The time from the beginning of duloxetine administration to the occurrence of SIADH, was 2 days to 36 months in 26 patients, with a median time of 3 days, except that one patient of overdose was 1 hour after administration, among which 21 patients occurred within 7 days. The main clinical manifestations of SIADH included nervous system symptoms (headache, dizziness, drowsiness, etc. in 20 patients), digestive system symptoms (nausea, vomiting, anorexia, etc. in 15 patients), and systemic symptoms (fatigue, limb weakness, etc. in 6 patients). When SIADH was diagnosed, the serum sodium level of the 27 patients was 98 to 132-mmol/L, with a median level of 117-mmol/L. The severity of SIADH with grade 1, 3, and 4 was in 1 (3.7%), 7 (25.9%), and 19 (70.4%) patients, respectively. After the diagnosis or suspicion of duloxetine-related SIADH, duloxetine was discontinued in all patients, fluid intake was restricted and sodium supplement was administered. Furosemide was given in 5 patients, and the serum sodium levels returned to normal within 2 to 15 days, with a median recovery time of 5 days. Conclusions Duloxetine- related SIADH mostly occurs within 7 days after the start of medication, and the degree is more serious. After stopping duloxetine, restricting the fluid intake, giving sodium supplement, and giving diuretics depending on the condition, the patient has a good prognosis.